It recommended generic SSRIs as first line choices, as they are "equally effective as other antidepressants and have a favourable risk–benefit ratio."
它建议将通用SSRIs作为第一线选择，因为它们“与其他抗抑郁药同样有效并且具有有利的风险-效益比”。